Advertisement

European Journal of Clinical Pharmacology

, Volume 28, Issue 1, pp 89–95 | Cite as

Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites

  • F. -A. Wiesel
  • J. Raaflaub
  • R. Kettler
Originals

Summary

The plasma concentrations of the MAO-inhibitor moclobemide (Ro 11-1163) were determined in six healthy male subjects after oral (tablets) administration. Effects on MAO activity in platelets and excretion of monoamine metabolites in urine were investigated. The design of the study was a double-blind cross-over study with single oral doses of placebo, 50, 100 and 200 mg of moclobemide. The elimination profile of the drug showed that the half life of the unchanged drug ranged between 1 and 2 h except in one subject with a half-life of about 4 h. The mean bioavailability calculated using flow model concepts was F=0.43 after 50 mg, F=0.47 after 100 mg and F=0.59 after 200 mg. The outlier with a t1/2 of 4 h was found to have a bioavailability of more than 0.80 after all 3 doses. The slightly increasing bioavailability with higher doses was interpreted as evidence of saturable hepatic first-pass elimination of the drug. MAO activity in platelets was measured before and 2, 6 and 24 h after drug administration. No inhibition of platelet MAO was obtained at any point in time or dose level, as to be expected since moclobemide preferentially inhibits MAO A. Urine excretion of the monoamine metabolites homovanillic acid (HVA), dihydroxyphenylacetic acid (DOPAC), 3-methoxy-4-hydroxy-phenylglycol (MOPEG) and 5-hydroxyindoleacetic acid (5-HIAA) was followed during 48 h after placebo, 50 and 200 mg of moclobemide. Time but not dose contributed significantly to the variability in excretion of the monoamine metabolites. An apparent reduction of HVA and DOPAC levels was obtained in the early phase after the administration of 200 mg of moclobemide. In 1 subject with a mild drug reaction a pronounced decrease in the levels of all the metabolites was obtained. In the other 5 subjects, the compound was very well tolerated with a few reported side-effects like increased activity, somnolence or sweatings. There was a slight but significant increase in blood pressure following 50 and 100 mg but not 200 mg of moclobemide.

Key words

moclobemide Ro 11-1163 pharmacokinetics bioavailability MAO activity in platelets monoamine metabolites in urine healthy volunteers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aasberg M, Montgomery S, Perris C, Schalling D, Sedvall G (1978) CPRS — The comprehensive psychopathological rating scale. Acta Psychiatr Scand 271 [Suppl]: 5–27CrossRefGoogle Scholar
  2. Bobon DP, Lepage-Goffioul G, Rossignol P, Gilot P, Adens A, Plomteux G, Breulet M (1979) Antidepressant effect and biological safety of a new MAO A-inhibitor, Ro 11-1163. Paper presented at the XVe Congrès International de Thérapeutique, Bruxelles, September 1979Google Scholar
  3. Bobon DP, Lepage-Goffioul G, Rossignol P (1980) Pilot open trial and time-blind videotaped evaluation of the antidepressant potency of a new Type A reversible MAO-inhibitor, Ro 11-1163. Paper presented at the 12th CINP Congress, Gothenburg, June 1980Google Scholar
  4. Burkard WP, Kettler R, Keller HH, Da Prada M (1978) A short-acting MAO inhibitor of novel chemical structure. Paper presented at the 7th International Congress of Pharmacology, Paris, 1978Google Scholar
  5. Da Prada M, Keller HH, Kettler R, Schaffner R, Pieri M, Burkard WP, Korn A, Haefely WE (1982) Ro 11-1163, a specific and short-acting MAO inhibitor with antidepressant properties. In: Kamijo, Usdin, Nagatsu (eds) Monoamine oxidase. Basic and clinical frontiers. Excerpta Medica, Amsterdam, pp 183–196Google Scholar
  6. Da Prada M, Kettler R, Keller HH, Haefely WE (1983) Neuro-chemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO A-inhibitor. Mod. Probl. Pharmacopsychiatry, 19: 231–245PubMedGoogle Scholar
  7. Da Prada M, Kettler R, Keller HH (1984) Elevation of adrenaline in rat brain by monoamine oxidase inhibitors. Clin Neuropharmacol, 7 [Suppl 1]: 684–685Google Scholar
  8. Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York, pp 48–96Google Scholar
  9. Härnryd C, Bjerkenstedt L, Björk K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel F-A, Wik G, Åberg-Wistedt A (1984) Clinical evaluation of sulpiride in schizophrenic patients — A doubleblind comparison chlorpromazine. Acta Psychiatr Scand 69 [Suppl 311]: 7–30CrossRefGoogle Scholar
  10. Idle JR, Smith RL (1979) Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev 9 [2]: 301–317PubMedCrossRefGoogle Scholar
  11. Korn A, Gasic S, Müller R, Hitzenberger G (1980) A new monoamine oxidase inhibitor which exerts a slightly increased tyramine sensitivity in man only. Abstract presented on World Conference on Clinical Pharmacology and Therapeutics, London, August 1980Google Scholar
  12. Krajl M (1965) A rapid micorfluoremetric determination of monoamine oxidase. Biochem Pharmacol 14: 1684–1686PubMedCrossRefGoogle Scholar
  13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275PubMedGoogle Scholar
  14. McEntire JE, Buchok SJ, Papermaster BW (1979) Determination of platelet monoamine oxidase activity in human platelet rich plasma. Biochem Pharmacol 28: 2345–2347PubMedCrossRefGoogle Scholar
  15. Raaflaub J, Haefelfinger P, Trautmann KH (1984) Single-dose pharmacokinetics of the MAO-inhibitor moclobemide in man. Arzneimittelforsch (Drug Research) 34: 80–82PubMedGoogle Scholar
  16. Swahn C-G, Sandgärde B, Wiesel F-A, Sedvall G (1976) Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology 48: 147–152CrossRefGoogle Scholar
  17. Swahn C-G, Wiesel F-A (1976) Determination of conjugated monoamine metabolites in brain tissue. J Neural Transm 39: 281–290PubMedCrossRefGoogle Scholar
  18. Tyrer P (1976) Towards rational therapy with monoamine oxidase inhibitors. Br J Psychiatry 128: 354–360PubMedCrossRefGoogle Scholar
  19. Wurtman RJ, Axelrod J (1963) A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 12: 1439–1441PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • F. -A. Wiesel
    • 1
  • J. Raaflaub
    • 2
  • R. Kettler
    • 2
  1. 1.Department of Psychiatry and PsychologyKarolinska HospitalStockholmSweden
  2. 2.Pharmaceutical Research DepartmentF. Hoffmann-La Roche Ltd.BasleSwitzerland

Personalised recommendations